학술논문
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
Document Type
article
Author
Pauline Maisonnasse; Yoann Aldon; Aurélien Marc; Romain Marlin; Nathalie Dereuddre-Bosquet; Natalia A. Kuzmina; Alec W. Freyn; Jonne L. Snitselaar; Antonio Gonçalves; Tom G. Caniels; Judith A. Burger; Meliawati Poniman; Ilja Bontjer; Virginie Chesnais; Ségolène Diry; Anton Iershov; Adam J. Ronk; Sonia Jangra; Raveen Rathnasinghe; Philip J. M. Brouwer; Tom P. L. Bijl; Jelle van Schooten; Mitch Brinkkemper; Hejun Liu; Meng Yuan; Chad E. Mire; Mariëlle J. van Breemen; Vanessa Contreras; Thibaut Naninck; Julien Lemaître; Nidhal Kahlaoui; Francis Relouzat; Catherine Chapon; Raphaël Ho Tsong Fang; Charlene McDanal; Mary Osei-Twum; Natalie St-Amant; Luc Gagnon; David C. Montefiori; Ian A. Wilson; Eric Ginoux; Godelieve J. de Bree; Adolfo García-Sastre; Michael Schotsaert; Lynda Coughlan; Alexander Bukreyev; Sylvie van der Werf; Jérémie Guedj; Rogier W. Sanders; Marit J. van Gils; Roger Le Grand
Source
Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
Subject
Language
English
ISSN
2041-1723
Abstract
Monoclonal antibodies show great promise in treating Covid-19 patients. Here, Maisonnasse, Aldon and colleagues report pre-clinical results for COVA1-18 and demonstrate that it reduces viral infectivity in three animal models with over 95% efficacy in macaques upper respiratory tract.